Maxwell Wealth Strategies Inc. Increases Holdings in Johnson & Johnson (NYSE:JNJ)

Maxwell Wealth Strategies Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 3.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,245 shares of the company’s stock after purchasing an additional 382 shares during the quarter. Maxwell Wealth Strategies Inc.’s holdings in Johnson & Johnson were worth $1,622,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Natixis Advisors LLC grew its position in shares of Johnson & Johnson by 19.6% during the 3rd quarter. Natixis Advisors LLC now owns 1,556,013 shares of the company’s stock valued at $252,168,000 after purchasing an additional 254,861 shares in the last quarter. Meridian Investment Counsel Inc. boosted its holdings in shares of Johnson & Johnson by 19.6% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock worth $3,667,000 after purchasing an additional 3,710 shares in the last quarter. Coastline Trust Co raised its stake in shares of Johnson & Johnson by 5.4% during the third quarter. Coastline Trust Co now owns 13,476 shares of the company’s stock worth $2,184,000 after acquiring an additional 687 shares in the last quarter. Vawter Financial Ltd. lifted its holdings in shares of Johnson & Johnson by 14.1% in the 3rd quarter. Vawter Financial Ltd. now owns 3,439 shares of the company’s stock worth $557,000 after acquiring an additional 426 shares during the last quarter. Finally, Simplify Asset Management Inc. boosted its stake in shares of Johnson & Johnson by 187.4% in the 3rd quarter. Simplify Asset Management Inc. now owns 67,601 shares of the company’s stock valued at $10,955,000 after purchasing an additional 44,081 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 1.4 %

Shares of JNJ opened at $154.00 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $370.77 billion, a price-to-earnings ratio of 22.29, a PEG ratio of 2.72 and a beta of 0.53. The company has a 50-day moving average of $161.35 and a 200 day moving average of $156.02. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $2.66 EPS. On average, research analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group decreased their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Citigroup raised their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $175.94.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 22.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.